Phaseline

Companies › Umecrine Cognition

Umecrine Cognition: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Gastroenterology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
golexanolone
Positive allosteric modulator of GABA-A receptor
GABRA1Phase 1Primary Biliary Cholangitis (PBC)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07304843golexanolonePhase 1Primary Biliary Cholangitis (PBC)GastroenterologySep 2026

Targets

GABRA1 (1)

Companies with the same targets

Ono Pharmaceutical Seaport Therapeutics Lipocine UCB Biopharma SRL Haisco Pharmaceutical Group Neurodawn Pharmaceutical SK Life Science Sedana Medical Acacia Pharma

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.